TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10597880

Group type: EXPERIMENTAL
Intervention: CEE + MPA (2.5 mg/day)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CEE + NG (0.05 mg/day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: CEE only (control)
Number of subjects: 9
Study: 8565031

Group type: EXPERIMENTAL
Intervention: Calcitonin salmon nasal spray (200 IU/d)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Calcitonin salmon nasal spray
Number of subjects: 81
Study: 2035326

Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline (n = 11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No treatment (n = 11)
Number of subjects: 22
Study: 7180926

Group type: EXPERIMENTAL
Intervention: CABCURVE cellulose acetate buterate (CAB) contact lenses
Number of subjects: 10

Group type: COMPARATOR
Intervention: Polymethyl methacrylate (PMMA) lenses
Number of subjects: 10

Group type: COMPARATOR
Intervention: Polycon lenses
Number of subjects: 10
Study: 31760586

Group type: EXPERIMENTAL
Intervention: CPAP via a facemask delivering 100% supplemental oxygen
Number of subjects: 185

Group type: COMPARATOR
Intervention: Standard O2 via nasal cannula or non-rebreather mask (control group)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: CPAP via a tight‐fitting mask
Number of subjects: 185
Study: 30675706

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation (CRT)
Number of subjects: 0
Study: 28485777

Group type: EXPERIMENTAL
Intervention: cisatracurium besylate combined with propofol and fentanyl
Number of subjects: 120

Group type: COMPARATOR
Intervention: 0.10 mg/kg vecuronium bromide combined with propofol and fentanyl
Number of subjects: 120
Study: 26276457

Group type: EXPERIMENTAL
Intervention: Stimulation phase (therapist held the needle)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control phase (needle untouched)
Number of subjects: 30
Study: 23400347

Group type: EXPERIMENTAL
Intervention: Parent-rated DSM-IV referenced anxiety scale
Number of subjects: 415
Study: 21052737

Group type: EXPERIMENTAL
Intervention: Airtraq(®) laryngoscope with a fiberoptic bronchoscope (FOB)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Airtraq(®) alone
Number of subjects: 8
Study: 18991973

Group type: EXPERIMENTAL
Intervention: Parenting Stress Index (PSI)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Family functioning measures (family support, family cohesion and adaptability, coping strategies, family needs, locus of control)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Griffiths Scales and Gross Motor Function measure
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Home Observation for Measuring the Environment
Number of subjects: 80
Study: 17304174

Group type: EXPERIMENTAL
Intervention: Levodopa (ON condition)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Levodopa (OFF condition)
Number of subjects: 20
Study: 16166613

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (500 microg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: COMPARATOR
Intervention: Cycling
Number of subjects: 17
Study: 12063951

Group type: EXPERIMENTAL
Intervention: Octreotide (200 micrograms/8 h)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Octreotide and Placebo
Number of subjects: 30
Study: 10615236

Group type: EXPERIMENTAL
Intervention: Counselling group led by professional psychologists (PG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Counselling group led by former smokers (SG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention group (NG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abstinent subjects
Number of subjects: 0
Study: 7813328

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heparin followed by oral anticoagulants
Number of subjects: 0
Study: 1958248

Group type: EXPERIMENTAL
Intervention: Visited and shown a leaflet and fact sheet (219)
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Visited and shown a video (263)
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Posted a leaflet and fact sheet (131)
Number of subjects: 737

Group type: COMPARATOR
Intervention: Not contacted at all (124)
Number of subjects: 737
Study: 7308554

Group type: EXPERIMENTAL
Intervention: Betnovate (betamethasone 17‐valerate, 0.1%) cream diluted to 50% in various vehicles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E45 dilution of betamethasone 17‐valerate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other formulations tested
Number of subjects: 0
Study: 30557295

Group type: EXPERIMENTAL
Intervention: Hippotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard outpatient physical therapy (PT)
Number of subjects: 0
Study: 28209333

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) supplementation (0.9 g GTE per day for 12 months)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group without GTE supplementation
Number of subjects: 176
Study: 26892863

Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Number of subjects: 1903

Group type: COMPARATOR
Intervention: E/C/F/TDF
Number of subjects: 1903

Group type: EXPERIMENTAL
Intervention: E/C/F/TAF and E/C/F/TDF
Number of subjects: 1903
Study: 24154935

Group type: EXPERIMENTAL
Intervention: Linagliptin 5mg once-daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Linagliptin 2.5mg twice-daily
Number of subjects: 16
Study: 21824990

Group type: EXPERIMENTAL
Intervention: Aliskiren (150 mg titrated to 300 mg once daily after 3 months)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 599
Study: 19838721

Group type: EXPERIMENTAL
Intervention: Blunt expansion of the uterine incision
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sharp expansion of the uterine incision
Number of subjects: 200
Study: 17236920

Group type: EXPERIMENTAL
Intervention: Simultaneous mandibular angle resection and bilateral sagittal split ramus osteotomy (BSSRO)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Bilateral sagittal split ramus osteotomy (BSSRO) only (Control)
Number of subjects: 26
Study: 14676992

Group type: EXPERIMENTAL
Intervention: Estradiol (50 microg transdermal 17beta‐estradiol)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 12431265

Group type: EXPERIMENTAL
Intervention: Home support from nurses who were certified lactation consultants
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard care and standard length of hospitalization
Number of subjects: 138
Study: 9660986

Group type: EXPERIMENTAL
Intervention: Oral cimetidine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Clarithromycin alone
Number of subjects: 12
Study: 7661232

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2706727

Group type: EXPERIMENTAL
Intervention: Proguanil plus sulfisoxazole
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Proguanil alone
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Sulfisoxazole
Number of subjects: 380

Group type: COMPARATOR
Intervention: Control group (vitamins)
Number of subjects: 380
Study: 1251156

Group type: EXPERIMENTAL
Intervention: Bactrim (2 x 2 tablets or ampoules daily)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo (parenterally and orally)
Number of subjects: 143
Study: 31691123

Group type: EXPERIMENTAL
Intervention: T1‐mVISTA
Number of subjects: 30

Group type: COMPARATOR
Intervention: T1‐MP‐RAGE
Number of subjects: 30
Study: 30354371

Group type: EXPERIMENTAL
Intervention: COMPASS-CP application
Number of subjects: 871
Study: 26589819

Group type: EXPERIMENTAL
Intervention: Amlodipine (n = 9048)
Number of subjects: 42418

Group type: EXPERIMENTAL
Intervention: Lisinopril (n = 9,054)
Number of subjects: 42418

Group type: COMPARATOR
Intervention: Chlorthalidone (n = 15,255)
Number of subjects: 42418

Group type: COMPARATOR
Intervention: Amlodipine vs Chlorthalidone
Number of subjects: 42418

Group type: COMPARATOR
Intervention: Lisinopril vs Chlorthalidone
Number of subjects: 42418
Study: 24388839

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (800 mg/160 mg) twice daily for 45 days, followed by tablet every 2 days
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo tablet every 2 days
Number of subjects: 95
Study: 22868974

Group type: EXPERIMENTAL
Intervention: Intensive intervention (four sessions, progressive reduction of smoking)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Brief intervention (single session, immediate cessation of smoking)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 92
Study: 20406615

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg daily)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Alfacalcidol (1 microg daily)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Cumulative glucocorticoid dose
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Presence of pre-existing fractures
Number of subjects: 201
Study: 18566487

Group type: EXPERIMENTAL
Intervention: Paling Perspective Scale
Number of subjects: 400

Group type: COMPARATOR
Intervention: Low-risk group
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: High-risk group
Number of subjects: 400

Group type: COMPARATOR
Intervention: Numerical presentation of risk comparisons
Number of subjects: 400
Study: 16053211

Group type: EXPERIMENTAL
Intervention: Pharmacological stabilization
Number of subjects: 94

Group type: COMPARATOR
Intervention: Mechanical stabilization (PCI)
Number of subjects: 94
Study: 12578765

Group type: EXPERIMENTAL
Intervention: Implantation of the ICL
Number of subjects: 291
Study: 10333345

Group type: EXPERIMENTAL
Intervention: Glucose 20% infusion at 0.3, 1.0, and 3.0 ml/min for 5 min each
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline 0.9% infusion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Glucose 20% infusion during local hyperinsulinaemia (insulin 0.05 mU/kg/min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline 0.9% infusion during local hyperinsulinaemia
Number of subjects: 8
Study: 8983282

Group type: EXPERIMENTAL
Intervention: Cisplatin dose adjustment to reach a target plasma concentration of total platinum (TP) of 2000 mu/l
Number of subjects: 27

Group type: COMPARATOR
Intervention: Cisplatin without dose adjustment
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cisplatin dose adjustment
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Etoposide (AUC)
Number of subjects: 27
Study: 1834864

Group type: EXPERIMENTAL
Intervention: Goserelin acetate plus flutamide (250 mg 3 times daily)
Number of subjects: 571

Group type: COMPARATOR
Intervention: Goserelin acetate alone
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Goserelin acetate plus flutamide
Number of subjects: 571
Study: 6161670

Group type: EXPERIMENTAL
Intervention: Leucomethylene blue staining
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no staining)
Number of subjects: 60
Study: 30580081

Group type: EXPERIMENTAL
Intervention: L-theanine (450–900 mg)
Number of subjects: 46
Study: 29266752

Group type: EXPERIMENTAL
Intervention: Active gas aspiration via a subdiaphragmatic port
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Passive-valve release via a subdiaphragmatic port valve opening
Number of subjects: 142

Group type: COMPARATOR
Intervention: Gas release from the surgical wound without port release (Control group)
Number of subjects: 142
Study: 26791438

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment twice a week for 2 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Varicocelectomy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 25247967

Group type: EXPERIMENTAL
Intervention: Thin-slice low-dose CT measurements in airways with a luminal diameter of 5 to 10 mm
Number of subjects: 100

Group type: COMPARATOR
Intervention: Thin-slice low-dose CT measurements in airways with a luminal diameter of 10 mm or greater
Number of subjects: 100
Study: 23060038

Group type: EXPERIMENTAL
Intervention: DFMO
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 20075648

Group type: EXPERIMENTAL
Intervention: Pagoclone
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Pagoclone (open-label extension)
Number of subjects: 132
Study: 18573585

Group type: EXPERIMENTAL
Intervention: omega-3 PUFAs 1.8 g/day
Number of subjects: 46

Group type: COMPARATOR
Intervention: placebo (olive oil)
Number of subjects: 46
Study: 15580457

Group type: EXPERIMENTAL
Intervention: Voice Handicap Index (VHI)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Voice Related Quality of Life (VRQOL)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (individuals without voice complaints)
Number of subjects: 52
Study: 12549684

Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 75

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 75
Study: 10863061

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (S + R)
Number of subjects: 366

Group type: COMPARATOR
Intervention: No further treatment (S alone)
Number of subjects: 366
Study: 9089857

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia with a constant subarachnoid infusion of 0.6 mg/h of bupivacaine and self-administration of 0.6 mg every 30 minutes
Number of subjects: 42

Group type: COMPARATOR
Intervention: Bolus administration of 3.75 mg of plain bupivacaine on request
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia with a constant subarachnoid infusion of 0.6 mg/h of bupivacaine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia with a continuous background infusion via microspinal catheters
Number of subjects: 42

Group type: COMPARATOR
Intervention: Bolus administration of bupivacaine
Number of subjects: 42
Study: 1443742

Group type: EXPERIMENTAL
Intervention: Isoflurane at 0.45 MAC
Number of subjects: 17

Group type: COMPARATOR
Intervention: N2O at 0.6 MAC
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Isoflurane (ED50)
Number of subjects: 17

Group type: COMPARATOR
Intervention: N2O (ED50)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Isoflurane and N2O
Number of subjects: 17

Group type: COMPARATOR
Intervention: Isoflurane vs N2O
Number of subjects: 17
Study: 3510540

Group type: EXPERIMENTAL
Intervention: Combination therapy with sympathomimetics and methylxanthines
Number of subjects: 157

Group type: COMPARATOR
Intervention: Epinephrine alone
Number of subjects: 157

Group type: COMPARATOR
Intervention: Isoproterenol alone
Number of subjects: 157

Group type: COMPARATOR
Intervention: Isoproterenol alone (in patients with severe airflow obstruction)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Epinephrine alone (in patients with severe airflow obstruction)
Number of subjects: 157
Study: 31929472

Group type: EXPERIMENTAL
Intervention: Simvastatin taken before bedtime
Number of subjects: 147

Group type: COMPARATOR
Intervention: Simvastatin taken after breakfast
Number of subjects: 147

Group type: COMPARATOR
Intervention: Simvastatin taken after dinner
Number of subjects: 147
Study: 29668699

Group type: EXPERIMENTAL
Intervention: Snus (Göteborgs Rapé)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Tobacco free snus (Onico)
Number of subjects: 29
Study: 26103979

Group type: EXPERIMENTAL
Intervention: Progressive spacing of TNF-blocker injections (S-arm)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Maintenance of TNF-blocker injections (M-arm)
Number of subjects: 137
Study: 25793955

Group type: EXPERIMENTAL
Intervention: Daily ingestion of a mixture of probiotics in addition to brushing teeth and using fluoridated toothpaste.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Brushing teeth and using fluoridated toothpaste without probiotics.
Number of subjects: 40
Study: 23232966

Group type: EXPERIMENTAL
Intervention: 1 g of cefazolin intramuscularly (reference group)
Number of subjects: 1046

Group type: COMPARATOR
Intervention: 10 mL of isotonic sodium chloride solution (study group)
Number of subjects: 1046
Study: 20646688

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 160

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study: 18236391

Group type: COMPARATOR
Intervention: FK (trough, 6‐10 ng/mL)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CsA (C2, 600‐1200 ng/mL)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: C2
Number of subjects: 60

Group type: COMPARATOR
Intervention: FK
Number of subjects: 60
Study: 16774104

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other clobetasol propionate preparations (solution, foam, cream, lotion, shampoo, emollient)
Number of subjects: 0
Study: 14660202

Group type: EXPERIMENTAL
Intervention: Fitness training added to treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Multifaceted treatment (without fitness training)
Number of subjects: 29
Study: 10741688

Group type: EXPERIMENTAL
Intervention: GH therapy (0.25 IU x kg per week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (first 6 months) then switched to GH therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GH therapy
Number of subjects: 20
Study: 8694313

Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron, 0.15 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 1552202

Group type: EXPERIMENTAL
Intervention: Live attenuated trivalent cold-recombinant influenza vaccine (10^5 TCID50 of each strain)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Live attenuated trivalent cold-recombinant influenza vaccine
Number of subjects: 32
Study: 31542838

Group type: EXPERIMENTAL
Intervention: Q1.6 smartphone application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classical measurements
Number of subjects: 0
Study: 31430268

Group type: EXPERIMENTAL
Intervention: RPh201 (20 mg) administered subcutaneously twice weekly
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (cottonseed oil vehicle) administered subcutaneously twice weekly
Number of subjects: 22
Study: 28419650

Group type: EXPERIMENTAL
Intervention: Combination therapy (solifenacin 5 mg/mirabegron 25 mg, increasing to 50 mg after week 4)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Solifenacin 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Solifenacin 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0
Study: 25304838

Group type: EXPERIMENTAL
Intervention: Butylscopolamine (20 mg intravenously immediately before the end of the operation)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no medication for prevention of CRBD)
Number of subjects: 99
Study: 23720276

Group type: EXPERIMENTAL
Intervention: Intramyocardial injection of autologous BM-MNC
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Combination of intramyocardial and intracoronary injection of autologous BM-MNC
Number of subjects: 54

Group type: COMPARATOR
Intervention: State-of-the-art medical management (Control)
Number of subjects: 54
Study: 21851883

Group type: EXPERIMENTAL
Intervention: Lenient rate control
Number of subjects: 517

Group type: COMPARATOR
Intervention: Strict rate control
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Female sex (independent variable)
Number of subjects: 517
Study: 20381972

Group type: EXPERIMENTAL
Intervention: 10-minute brief intervention
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 50-minute brief intervention
Number of subjects: 114

Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 114
Study: 17682094

Group type: EXPERIMENTAL
Intervention: Ceftaroline (600 mg every 12 h)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard therapy (i.v. vancomycin 1 g every 12 h with or without adjunctive i.v. aztreonam 1 g every 8 h)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ceftaroline
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 100
Study: 15026871

Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion
Number of subjects: 61
Study: 12097849

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 130/0.4
Number of subjects: 106

Group type: COMPARATOR
Intervention: 0.9% saline solution (placebo)
Number of subjects: 106
Study: 9421387

Group type: EXPERIMENTAL
Intervention: Troglitazone (200 mg once daily)
Number of subjects: 29
Study: 7652582

Group type: EXPERIMENTAL
Intervention: INF-alpha therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of INF-alpha therapy with other chemotherapeutic agents and/or biologicals
Number of subjects: 0
Study: 2673315

Group type: EXPERIMENTAL
Intervention: Felodipine (chronic oral treatment for 8 weeks)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Felodipine (acute intravenous administration)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Felodipine (chronic oral treatment)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 790413

Group type: EXPERIMENTAL
Intervention: Oral fluphenazine (5-20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Depot fluphenazine (25 mg/q 3 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both oral and depot fluphenazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benztropine (as needed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral and depot fluphenazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dosage equivalence
Number of subjects: 0
Study: 31763307

Group type: EXPERIMENTAL
Intervention: Microdebrider endoscopic sinus surgery (ESS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional endoscopic sinus surgery (ESS)
Number of subjects: 60
Study: 28976825

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional gauze dressings
Number of subjects: 104